MX2011009846A - Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno. - Google Patents

Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.

Info

Publication number
MX2011009846A
MX2011009846A MX2011009846A MX2011009846A MX2011009846A MX 2011009846 A MX2011009846 A MX 2011009846A MX 2011009846 A MX2011009846 A MX 2011009846A MX 2011009846 A MX2011009846 A MX 2011009846A MX 2011009846 A MX2011009846 A MX 2011009846A
Authority
MX
Mexico
Prior art keywords
aliskiren
valsartan
fixed dose
dose combination
galenical formulations
Prior art date
Application number
MX2011009846A
Other languages
English (en)
Inventor
Shoufeng Li
Wei-Qin Tong
Indrajit Ghosh
Sudha Vippagunta
Hong Wen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2011009846A publication Critical patent/MX2011009846A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica oral de dosis fija, la cual comprende: a) una cantidad terapéuticamente efectiva de Alisquireno, o una sal farmacéuticamente aceptable del mismo, b) una cantidad terapéuticamente efectiva de Valsartan, o una sal farmacéuticamente aceptable del mismo, c) un desintegrante, y d) un desintegrante adicional que es un polisacárido.
MX2011009846A 2009-03-20 2010-03-18 Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno. MX2011009846A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16189109P 2009-03-20 2009-03-20
PCT/US2010/027757 WO2010107971A1 (en) 2009-03-20 2010-03-18 Galenical formulations of a fixed dose combination of valsartan and aliskiren

Publications (1)

Publication Number Publication Date
MX2011009846A true MX2011009846A (es) 2011-09-29

Family

ID=42594917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009846A MX2011009846A (es) 2009-03-20 2010-03-18 Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.

Country Status (13)

Country Link
US (1) US20120009257A1 (es)
EP (1) EP2408427A1 (es)
JP (1) JP2012520895A (es)
KR (1) KR20110130491A (es)
CN (1) CN102348452A (es)
AR (1) AR075880A1 (es)
AU (1) AU2010226620A1 (es)
BR (1) BRPI1009468A2 (es)
CA (1) CA2755487A1 (es)
MX (1) MX2011009846A (es)
RU (1) RU2011142081A (es)
TW (1) TW201039866A (es)
WO (1) WO2010107971A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014405049B2 (en) * 2014-08-29 2017-04-20 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AR048431A1 (es) 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
WO2009040427A1 (en) * 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of organic compounds
WO2009045796A1 (en) * 2007-09-28 2009-04-09 Novartis Ag Pharmaceutical combination of aliskiren and valsartan
WO2009045795A2 (en) * 2007-09-28 2009-04-09 Novartis Ag Galenical formulations of aliskiren and valsartan
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
MX2011009844A (es) * 2009-03-20 2011-09-29 Novartis Ag Composicion farmaceutica que comprende alisquireno.
US9959508B2 (en) 2014-03-20 2018-05-01 CloudMade, Inc. Systems and methods for providing information for predicting desired information and taking actions related to user needs in a mobile device

Also Published As

Publication number Publication date
BRPI1009468A2 (pt) 2016-03-01
CA2755487A1 (en) 2010-09-23
WO2010107971A1 (en) 2010-09-23
KR20110130491A (ko) 2011-12-05
AR075880A1 (es) 2011-05-04
CN102348452A (zh) 2012-02-08
JP2012520895A (ja) 2012-09-10
AU2010226620A1 (en) 2011-09-22
RU2011142081A (ru) 2013-04-27
EP2408427A1 (en) 2012-01-25
US20120009257A1 (en) 2012-01-12
TW201039866A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
UA106634C2 (uk) Тверда фармацевтична дозована форма
TN2010000135A1 (en) Galenical formulations of organic compounds
PH12012502161A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
PH12013500172A1 (en) Use of binders for manufacturing storage stable formulations
MX343689B (es) Formulaciones combinadas de darunavir.
PT2205279E (pt) Associação farmacêutica de aliscireno e valsartan
IL215826A (en) Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it.
MX2015001917A (es) Composiciones farmaceuticas de memantina.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
MX341976B (es) Formulaciones de darunavir.
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
PH12015500823A1 (en) Modified release formulations for oprozomib
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
SI2081904T1 (sl) Aripiprazol hemifumarat in postopek za njegovo pripravo
MX2012002631A (es) Capsulas con aroma.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
JO3239B1 (ar) تركيبات جالينية من مركبات عضوية
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
NZ707033A (en) Dispersible nimorazole tablet
MX2011009844A (es) Composicion farmaceutica que comprende alisquireno.
WO2012005709A3 (en) Pharmaceutical composition comprising valsartan
TN2011000100A1 (en) Galenical formulations of organic compounds
UA105513C2 (uk) Лікарська форма уповільненого вивільнення глюкозаміну

Legal Events

Date Code Title Description
FA Abandonment or withdrawal